A5102820281- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Lipids, and Metabolism
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
Peking University
2024
Jilin University
2023-2024
First Hospital of Jilin University
2023-2024
Abstract The 2023 update of the Chinese Society Clinical Oncology (CSCO) Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting latest advancements evidence‐based medicine, healthcare resource availability, precision medicine. These updates address differences epidemiological characteristics, clinicopathological features, tumor biology, patterns, drug selections between Eastern Western gastric patients. Key revisions include a structured...
Abstract Chemotherapeutic efficacy is seriously impeded by chemoresistance in more than half of hepatocellular carcinoma (HCC) patients. However, the mechanisms involved chemotherapy-induced upregulation chemoresistant genes are not fully understood. Here, this study unravels a novel mechanism controlling nuclear acetyl-CoA production to activate transcription HCC. NAT10 upregulated HCC tissues and its correlated with poor prognosis also cells. Targeting increases cytotoxicity chemotherapy...
Abstract Background This study aimed to assess the activity of apatinib plus toripalimab in second line for patients with advanced gastric or esophagogastric junction cancer (GC/EGJC). Methods In this open-label, phase II, randomized trial, GC/EGJC who progressed after first-line chemotherapy were enrolled and received 250 mg per day 240 on 1 3 weeks (arm A) physician’s choice (PC, arm B). The primary endpoint was 1-year survival rate. Progression-free (PFS), overall (OS), response rate...
Colorectal cancer is the third most common and second leading cause of death. There are limited therapeutic options for treatment locally advanced or metastatic colorectal cancers which fail first-line chemotherapy. Phase I/II studies showed that combined application raltitrexed irinotecan has significant synergistic effect acceptable toxicity. However, these previous have relatively small sample size. This a prospective open-label, single-arm, multi-center, II trial. Brief inclusion...
<title>Abstract</title> Background Colorectal cancer is the third most common and second leading cause of death. There are limited therapeutic options for treatment locally advanced or metastatic colorectal cancers which fail first-line chemotherapy. Phase I/II studies showed that combined application raltitrexed irinotecan has significant synergistic effect acceptable toxicity. However, these previous have relatively small sample size. Methods This a prospective open-label, single-arm,...